1. Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials
- Author
-
Hamid, Arsalan, Anker, Markus S, Ruckdeschel, John C, Khan, Muhammad Shahzeb, Tharwani, Arsal, Oshunbade, Adebamike A, Kipchumba, Rodney K, Thigpen, Samuel C, Anker, Stefan D, Fonarow, Gregg C, Hall, Michael E, and Butler, Javed
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Patient Safety ,Cardiovascular ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Heart Disease ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Breast Neoplasms ,Female ,Humans ,Troponin ,cancer therapy ,cardio-oncology ,cardiovascular disease ,pharmacotherapy ,safety ,cardio‐oncology ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Several cancer therapies have been associated with cardiovascular harm in early-phase clinical trials. However, some cardiovascular harms do not manifest until later-phase trials. To limit interdisease variability, we focused on breast cancer. Thus, we assessed the reporting of cardiovascular safety monitoring and outcomes in phase 2 and 3 contemporary breast cancer clinical trials. Methods and Results We searched Embase and Medline records for phase 2 and 3 breast cancer pharmacotherapy trials. We examined exclusion criterion as a result of cardiovascular conditions, adverse cardiovascular event reporting, and cardiovascular safety assessment through cardiovascular imaging, ECG, troponin, or natriuretic peptides. Fisher's exact test was utilized to compare reporting. Fifty clinical trials were included in our study. Patients were excluded because of cardiovascular conditions in 42 (84%) trials. Heart failure was a frequent exclusion criterion (n=31; 62% trials). Adverse cardiovascular events were reported in 43 (86%) trials. Cardiovascular safety assessments were not reported in 23 (46%) trials, whereas natriuretic peptide and troponin assessments were not reported in any trial. Cardiovascular safety assessments were more frequently reported in industry-funded trials (69.2% versus 0.0%; P
- Published
- 2022